Soyeon Lee, Hye One Kim, Song-Yi Baek, Narendra Kumar
{"title":"A Retrospective Analysis of the Clinical Response and Safety of Radiofrequency Microneedling Treatment in Managing Acne Vulgaris.","authors":"Soyeon Lee, Hye One Kim, Song-Yi Baek, Narendra Kumar","doi":"10.1093/asjof/ojag097","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Radiofrequency (RF) microneedling is increasingly used for acne management; however, real-world evidence for its clinical effects and safety remains limited.</p><p><strong>Objectives: </strong>The aim of this study was to describe the clinical response and safety of POTENZA RF microneedling (RFMN) for acne vulgaris in routine practice.</p><p><strong>Methods: </strong>The authors retrospectively analyzed data from adults treated at a tertiary dermatology center in Seoul, Republic of Korea. Adult patients (≥18 years) with clinically diagnosed acne vulgaris who received POTENZA RFMN treatment were included. The primary outcome was clinical improvement (assessed by the physician and/or reduction in lesion counts). Secondary outcomes included adverse events (AEs). Continuous variables were summarized per distribution.</p><p><strong>Results: </strong>The cohort included 50 patients (median age, 24 years; 60% male) with predominantly Fitzpatrick skin types III. All procedures used bipolar RF (50% medium, 50% high); no boosters. Median sessions were 3. Clinical improvement occurred in 94% (47/50). Lesion counts decreased from 45 to 18.5 (<i>P</i> < .001). The mean percentage reduction was 48.3% ± 24.5%. AEs occurred in 10% (5/50), all mild/transient (erythema, pruritus, and stinging), and no serious AEs.</p><p><strong>Conclusions: </strong>In real-world practice, POTENZA RFMN was associated with high clinical improvement, substantial lesion reduction, excellent tolerability, and universal patient-reported benefits. These findings support its pragmatic use for acne in patients with Fitzpatrick skin types III and IV and warrant confirmation in prospective controlled studies.</p><p><strong>Level of evidence: </strong>4 (Therapeutic).</p>","PeriodicalId":72118,"journal":{"name":"Aesthetic surgery journal. Open forum","volume":"8 ","pages":"ojag097"},"PeriodicalIF":1.9000,"publicationDate":"2026-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13457912/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Aesthetic surgery journal. Open forum","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/asjof/ojag097","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Radiofrequency (RF) microneedling is increasingly used for acne management; however, real-world evidence for its clinical effects and safety remains limited.
Objectives: The aim of this study was to describe the clinical response and safety of POTENZA RF microneedling (RFMN) for acne vulgaris in routine practice.
Methods: The authors retrospectively analyzed data from adults treated at a tertiary dermatology center in Seoul, Republic of Korea. Adult patients (≥18 years) with clinically diagnosed acne vulgaris who received POTENZA RFMN treatment were included. The primary outcome was clinical improvement (assessed by the physician and/or reduction in lesion counts). Secondary outcomes included adverse events (AEs). Continuous variables were summarized per distribution.
Results: The cohort included 50 patients (median age, 24 years; 60% male) with predominantly Fitzpatrick skin types III. All procedures used bipolar RF (50% medium, 50% high); no boosters. Median sessions were 3. Clinical improvement occurred in 94% (47/50). Lesion counts decreased from 45 to 18.5 (P < .001). The mean percentage reduction was 48.3% ± 24.5%. AEs occurred in 10% (5/50), all mild/transient (erythema, pruritus, and stinging), and no serious AEs.
Conclusions: In real-world practice, POTENZA RFMN was associated with high clinical improvement, substantial lesion reduction, excellent tolerability, and universal patient-reported benefits. These findings support its pragmatic use for acne in patients with Fitzpatrick skin types III and IV and warrant confirmation in prospective controlled studies.